mao

MAO-B-IN-8 is a highly potent and reversible inhibitor of monoamine oxidase-B (MAO-B), also inhibiting microglial production of neuroinflammatory mediators. This compound is specifically designed for research on neurodegenerative diseases [1].

AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively. [AChE/BChE/MAO-B-IN-1] had a neuroprotective effect and was not significantly cytotoxic.

MAO-B-IN-30 is a selective and potent MAO-B inhibitor that crosses the blood-brain barrier with antiproliferative activity and inhibits both MAO-A and MAO-B.MAO-B-IN-30 reduces the levels of TNF-alpha, IL-6, and NF-kB in organisms, and can be used to study Parkinson's-type neurological disorders.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC50 values of 0.51 μM and 7.00 μM, respectively. It attenuates H2O2-induced cellular damage due to its strong ROS scavenging properties.

MAO-IN-M30 dihydrochloride is a highly potent non-selective inhibitor of MAO-A and MAO-B (IC50 < 0.1 μM). MAO-IN-M30 dihydrochloride is orally active and can cross the blood-brain barrier. It is an effective iron chelator and free radical scavenger. MAO-IN-M30 dihydrochloride has neuroprotective activity in in vitro and in vivo models of Parkinson's disease (PD). It increases brain dopamine, serotonin and norepinephrine and can serve as a lead drug for the development of multifunctional drugs to treat various neurodegenerative diseases.

MAO-B ligand-1 is a selective MAO-B inhibitor.

2614W94 is a selective inhibitor of MAO-A with IC50 of 5 nM and Ki of 1.6 nM.

CX-157 (KP 157) is a novel monoamine oxidase-A (MAO-A) inhibitor for the study of depression-like neurological disorders and cancer.

BW-1370U87 is a reversible competitive monoamine oxidase-A inhibitor for the study of depression and other CNS disorders.

Esuprone (LU-43839) is a novel reversible and highly selective MAO-A inhibitor with anticonvulsant activity for the treatment of depression.

Sembragiline (EVT-302) is a selective MAO-B inhibitor for the study of Alzheimer's disease (AD).

Ladostigil (Ladostigil free base) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) with inhibitory effects on MAO-B and AChE, with IC50 values of 37.1 and 31.8 μM, respectively.Ladostigil possesses anti-inflammatory, antioxidant, and neuroprotective activities, and may be used in studies of depression and Alzheimer's disease.

Femoxetine is a 5-HT inhibitor with antidepressant activity that potentiates morphine-induced anti-injury feelings and inhibits MAO-A and MAO-B required for the production of high exercise capacity in mice.

Atibeprone is a MAO-B inhibitor with antidepressant activity for the study of Parkinson's disease.

Allylthiourea (Thiosinamine), a metabolic inhibitor, specifically suppresses ammonia oxidation.

Furazolidone (Furoxone), a nitrofuran derivative, inhibits AML1-ETO transformed cells with IC50 value of 12.7 μM. It is antibacterial and antiprotozoal activity,

Tranylcypromine (2-PCPA) hydrochloride (SKF-385 HCl), a Monoamine Oxidase inhibitor, is effective in the treatment of major depression, dysthymic disorder, and atypical depression.

Hydroxylamine hydrochloride(Hydroxylammonium chloride) is a selective and potent monoamine oxidase (MAO) inhibitor with inhibitory effects on platelet aggregation.Hydroxylamine hydrochloride is an intermediate in organic synthesis and can be used to synthesize other active compounds.

Hydralazine hydrochloride (Apresoline) is the hydrochloride salt of hydralazine, a phthalazine derivative with antihypertensive and potential antineoplastic activities. Hydralazine alters intracellular calcium release and interferes with smooth muscle cell calcium influx, resulting in arterial vasodilatation. This agent also inhibits the phosphorylation of myosin protein and chelation of trace metals required for smooth muscle contraction, resulting in an increase in heart rate, stroke volume, and cardiac output. In addition to its cardiovascular effects, hydralazine inhibits DNA methyltransferase, which may result in inhibition of DNA methylation in tumor cells.

Tedizolid (DA-7157)is a novel oxazolidinone-class antibiotic that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit of the ribosome.

Rosmarinic acid (Labiatenic acid) is widely found in plants and has antioxidant, anti-inflammatory, and antibacterial activities. It inhibits MAO-A, MAO-B, and COMT with IC50 of 50.1, 184.6, and 26.7 μM respectively.

Paeonol (Peonol) is an active extraction from Paeonia suffruticosa. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.